Search results for "HEPATITIS"

showing 10 items of 1578 documents

Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany - Limitations of th…

2010

Summary Since the introduction of model for end-stage liver disease (MELD) in 2006, post-orthotopic liver transplantation (OLT) survival in Germany has declined. The aim of this study was to evaluate risk factors and prognostic scores for outcome. All adult OLT recipients in seven German transplant centers after MELD implementation (December 2006–December 2007) were included. Recipient data were analyzed for their influence on 1-year outcome. A total of 462 patients (mean calculated MELD = 20.5, follow-up: 1 year) were transplanted for alcoholic cirrhosis (33.1%), hepatocellular carcinoma (26.6%), Hepatitis-C (17.1%), Hepatitis-B (9.5%), primary sclerosing cholangitis (5.6%) and late graft-…

AdultMaleReoperationmedicine.medical_specialtyAlcoholic liver diseaseCarcinoma HepatocellularTissue and Organ ProcurementAdolescentmedicine.medical_treatmentMedizinLiver transplantationSeverity of Illness IndexGastroenterologyPrimary sclerosing cholangitisEnd Stage Liver DiseaseLiver diseaseModel for End-Stage Liver DiseaseRisk FactorsGermanyInternal medicinemedicineHumansRisk factorIntensive care medicineAgedRetrospective StudiesHepatitisTransplantationHealth Care Rationingbusiness.industryLiver NeoplasmsOdds ratioMiddle Agedmedicine.diseaseSurvival AnalysisLiver Transplantationbody regionsTreatment OutcomeFemalebusiness
researchProduct

Orthotopic liver transplantation in a malignant hyperthermia susceptible patient.

2005

We present a patient with hepatitis C and D and hepatocellular carcinoma who underwent preoperative evaluation for orthotopic liver transplantation. In his past medical history, he reported a life-threatening event during tonsillectomy in 1975. Intubation was impossible due to extreme jaw muscle tension, followed by excessive elevation in body temperature, tachycardia, and coma for a few days. We evaluated him for malignant hyperthermia, according to the European Malignant Hyperthermia Group Protocol, and found him highly positive in both the halothane and caffeine test, respectively. Three months later, we performed an orthotopic liver transplantation. During retransplantation 4 years late…

AdultMaleReoperationmedicine.medical_specialtyCarcinoma HepatocellularAnesthesia GeneralDantroleneMonitoring IntraoperativemedicineCarcinomaHumansAprotininPast medical historybusiness.industryLiver NeoplasmsMalignant hyperthermiaHemodynamicsHepatitis CPerioperativemedicine.diseaseHepatitis BHepatitis DSurgeryLiver TransplantationAnesthesiology and Pain MedicineAnesthesiaHepatocellular carcinomabusinessMalignant Hyperthermiamedicine.drugJournal of clinical anesthesia
researchProduct

Long-Term Results After Liver Transplantation With “Livers That Nobody Wants” Within Eurotransplant: A Center's Experience

2008

Abstract Background Orthotopic liver transplantation (OLT) represents the only curative treatment for end-stage liver disease, but its application is limited because of organ shortages. The purpose of this study was to review the long-term outcomes after OLT during a 2-year period of 45 rescue offers organs within Eurotransplant. Patients and Methods Forty-five deceased donor liver allografts had been officially offered to and rejected by other transplantation centers 162 times prior to our acceptance. Data analysis addressed recurrence of primary disease, ischemic-type biliary lesions (ITBL), re-evaluation or relisting for OLT, re-OLT, as well as overall patient and graft survivals. Result…

AdultMaleReoperationmedicine.medical_specialtyOrthotopic liver transplantationmedicine.medical_treatmentLiver transplantationLiver diseaseCadavermedicineHumansTransplantation HomologousSurvivorsSurvival rateTransplantationbusiness.industryPatient SelectionGraft SurvivalHepatitis CLong term resultsMiddle Agedmedicine.diseaseTissue DonorsLiver TransplantationSurgerySurvival RateTransplantationTreatment Outcomesurgical procedures operativeFemaleSurgeryGraft survivalbusinessLiver FailureTransplantation Proceedings
researchProduct

Human Hepatocyte Transplantation in Patients with Hepatic Failure Awaiting a Graft

2012

<b><i>Background:</i></b> Hepatocyte transplantation (HT) has the potential to become a promising treatment to temporarily support liver function in patients with liver failure. <b><i>Methods:</i></b> Two patients, who had already received a liver transplant (LT) in the past, with an end-stage liver disease due to recurrent hepatitis C virus cirrhosis, suffering acute-on-chronic liver failure while on the waiting list for an LT, received HT as a bridge to whole-organ retransplantation. After HT and during intensive care unit admission, blood tests and ammonia levels were determined every 12 and 24 h, respectively, before and after each hepatoc…

AdultMaleReoperationmedicine.medical_specialtyTime FactorsWaiting Listsmedicine.medical_treatmentLiver transplantationChronic liver diseaseGastroenterologyEnd Stage Liver DiseaseHepatocyte transplantationLiver Function TestsAmmoniaInternal medicinemedicineHumansIn patientmedicine.diagnostic_testbusiness.industryHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseLiver TransplantationTransplantationHepatocytesSurgeryLiver functionbusinessLiver function testsEuropean Surgical Research
researchProduct

Transmission of hepatitis B and hepatitis delta viruses in the households of chronic hepatitis B surface antigen carriers: A regression analysis of i…

1991

Abstract To evaluate whether clinical and laboratory features of a hepatitis B surface antigen (HBsAg) carrier can predict risks of infection, its chronicity, and the development of liver disease among close contacts, the authors studied a cohort of 994 first degree relatives or cohabitants (household contacts) of 226 non-drug-addicted chronic HBsAg carriers (index cases), of whom 77% had liver disease and 26% were superinfected by hepatitis D virus (HDV). A logistic form of regression analysis was used to assess the role of each feature in the index case as predictor of hepatitis B virus (HBV)- and HDV-related outcomes among household contacts. Six models of risk, expressed as odds ratios,…

AdultMaleRiskHepatitis B virusHBsAgAdolescentEpidemiologymedicine.disease_causeLiver diseaseHumansMedicineHepatitis AntibodiesChildIndex caseAgedFamily HealthHepatitis B virusHepatitis B Surface Antigensbusiness.industryHepatobiliary diseaseInfantvirus diseasesMiddle AgedHepatitis BHepatitis Bmedicine.diseaseHepatitis Ddigestive system diseasesItalyHBeAgChild PreschoolCarrier StateDNA ViralMutationImmunologyRegression AnalysisFemaleHepatitis D virusHepatitis Delta Virusbusiness
researchProduct

Statin use and non-alcoholic steatohepatitis in at risk individuals.

2015

Background & Aims Excess hepatic free cholesterol contributes to the pathogenesis of non-alcoholic steatohepatitis, and statins reduce cholesterol synthesis. Aim of this study was to assess whether statin use is associated with histological liver damage related to steatohepatitis. Methods The relationship between statin use, genetic risk factors, and liver damage was assessed in a multi-center cohort of 1201 European individuals, who underwent liver biopsy for suspected non-alcoholic steatohepatitis. Results Statin use was recorded in 107 subjects, and was associated with protection from steatosis, NASH, and fibrosis stage F2-F4, in a dose-dependent manner (adjusted p <0.05 for all).…

AdultMaleRiskmedicine.medical_specialtyStatinmedicine.drug_classBiopsyGastroenterologyNon-alcoholic Fatty Liver DiseaseInternal medicinemedicineHumansSteatosiPNPLA3AgedHepatologymedicine.diagnostic_testbusiness.industryNASHStatinMembrane ProteinsLipaseHepatologyMiddle AgedImpaired fasting glucosemedicine.diseaseCholesterolEndocrinologyLogistic ModelsLiverLiver biopsyCohortFemaleSteatosisSteatohepatitisHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessNon-alcoholic steatohepatitiTM6SF2Journal of hepatology
researchProduct

Sarcopenia as prognostic factor for survival after orthotopic liver transplantation

2020

Background and aim Body composition has emerged as a prognostic factor for end-stage liver disease. We therefore investigated muscle mass, body fat and other clinical-pathological variables as predictors of posttransplant survival. Methods A total of 368 patients, who underwent orthotopic liver transplantation (OLT) at our institution, were assessed prior to OLT and followed for a median of 9.0 years (range 2.0-10.0 years) after OLT. Psoas, erector spinae and the combined paraspinal muscle area, as well as the corresponding indices normalized by body-height squared, were quantified by a lumbar (L3) cross-sectional computed tomography. In addition, absolute body fat and bone density were est…

AdultMaleSarcopeniamedicine.medical_specialtyBone densityUrologyEnd Stage Liver Disease03 medical and health sciencesLiver disease0302 clinical medicineLumbarErector spinae musclesHumansMedicineRetrospective StudiesAnatomy Cross-SectionalHepatologybusiness.industryHazard ratioGastroenterologyHepatitis CMiddle AgedPrognosismedicine.diseaseConfidence intervalLiver Transplantation030220 oncology & carcinogenesisSarcopeniaBody CompositionFemale030211 gastroenterology & hepatologyTomography X-Ray ComputedbusinessEuropean Journal of Gastroenterology & Hepatology
researchProduct

HCV genotypes in Sicily: is there any evidence of a shift?

2009

The distribution of HCV strains in any area is characterized by a relative prevalence of one genotype, and a number of less prevalent types. In some Western countries a change from the prevalent HCV genotype 1 to genotypes 3 and 4 has been reported in the last decade. In order to assess possible variations of the distribution of HCV genotypes in Sicily, a southern region of Italy, a hospital-based cohort, collected prospectively, of 3,209 subjects with chronic HCV infection was surveyed, comparing the distribution of HCV genotypes during two consecutive periods, from 1997 to 2002 and from 2003 to 2007, according to age and gender. The results show that genotype 1b, which has been historical…

AdultMaleSettore MED/07 - Microbiologia E Microbiologia ClinicaAdolescentGenotypeHepatitis C virusHepacivirusmedicine.disease_causeCohort StudiesFlaviviridaeYoung AdultVirologyGenotypemedicinePrevalenceHumansProspective StudiesChildGenotypingSicilyAgedAged 80 and overSettore MED/12 - GastroenterologiaMolecular EpidemiologyMolecular epidemiologybiologybusiness.industryInfantHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseasebiology.organism_classificationVirologyhepatitis C virusmolecular epidemiology genotypingHCV prevalencechronic hepatitisInfectious DiseasesCohort effectChild PreschoolCohortFemalebusinessJournal of medical virology
researchProduct

Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B…

2009

Background The high degree of diversity of the hepatitis B virus (HBV) quasispecies in chronically infected individuals raises the possibility that HBV genetic variants favouring resistance to nucleoside/nucleotide analogues (NAs) might pre-exist to treatment. The aim of this study was to investigate the genetic variability of the entire HBV reverse transcriptase (RT) domain and of the overlapping S gene in a large series of untreated hepatitis B surface antigen carriers and in lamivudine (3TC)-resistant patients. Methods Sequencing analysis of the entire HBV RT domain of isolates from 100 untreated (treatment- naive group) and 59 3TC-resistant (3TC-resistant group) consecutive patients wit…

AdultMaleSettore MED/07 - Microbiologia E Microbiologia ClinicaHepatitis B virusAdult; Aged; Drug Resistance; Viral; Female; Genetic Variation; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B; Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; RNA-Directed DNA Polymerase; Reverse Transcriptase Inhibitors; Sequence Analysis; DNA; Treatment OutcomeDrug ResistanceViral quasispeciesmedicine.disease_causeVirusHepatitis B ChronicOrthohepadnavirusDrug Resistance ViralmedicineHumansPharmacology (medical)ViralChronicAgedPharmacologyHepatitis B virusSettore MED/12 - GastroenterologiaHepatitis B Surface AntigensbiologyReverse-transcriptase inhibitorLamivudineGenetic VariationRNA-Directed DNA PolymeraseSequence Analysis DNADNAMiddle Agedbiology.organism_classificationHepatitis BVirologyReverse transcriptaseInfectious DiseasesTreatment OutcomeHepadnaviridaeLamivudineMutationReverse Transcriptase InhibitorsHBV reverse transcriptase gene S lamivudine resistantFemaleSequence Analysismedicine.drug
researchProduct

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

2002

Background Treatment with peginterferon alfa-2a alone produces significantly higher sustained virologic responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C. Methods A total of 1121 patients were randomly assigned to treatment and received at least one dose of study medication, consisting of 180 μg of peginterferon alfa-2a once weekly plus daily ribavirin (1000 or 1200 mg, depending on body weight), weekly peginterferon alfa-2a plus daily pl…

AdultMaleSimeprevirmedicine.medical_specialtyGenotypeTaribavirinHepacivirusInterferon alpha-2Antiviral AgentsGastroenterologyPolyethylene GlycolsTelaprevirchemistry.chemical_compoundstomatognathic systemhemic and lymphatic diseasesInternal medicineBoceprevirRibavirinHumansMedicinebusiness.industryRibavirinInterferon-alphavirus diseasesGeneral MedicineHepatitis C ChronicRecombinant Proteinsdigestive system diseasesInterleukin 28BchemistryImmunologyRNA ViralPeginterferon alfa-2bDrug Therapy CombinationFemalebusinesstherapeuticsmedicine.drugPeginterferon alfa-2a
researchProduct